Table 1.
Psychiatric adverse effects in DAAs
| Telaprevir trials | Boceprevir trials | |||||
|---|---|---|---|---|---|---|
| |
ADVANCE[[4]] |
ILLUMINATE*[[31]] |
REALIZE[[32]] |
SPRINT-1[[33]] |
SPRINT-2[[5]] |
RESPOND-2[[34]] |
| Psychiatric side effect |
|
|
|
|
|
|
| Fatigue |
57% (57%) |
68% |
55% (40%) |
68% (55%) |
53% (60%) |
54% (50%) |
| Insomnia |
32% (31%) |
31% |
26% (26%) |
28% (38%) |
33% (32%) |
30% (20%) |
| Irritability |
22% (18%) |
- |
14% (16%) |
- |
22% (24%) |
19% (13%) |
| Depression |
18% (22%) |
- |
9% (14%) |
- |
23% (22%) |
12% (15%) |
| Anxiety | 10% (12%) | - | - | - | - | - |
% - percent for study arm corresponding to current standard of care for DAA.
(%) – percent for pegylated IFNα and Ribavirin treatment arm.
*ILLUMINATE – did not have pegylated IFNα and Ribavirin treatment arm.